Comparison of S-1 –cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials

ConclusionOur pooled analysis supports the use of SP in the first-line setting for patients with HER2-negative advanced or recurrent GC with a recurrence-free interval of  ≥ 6 months.Clinical trial registrationThe HERBIS-2 trial was registered with UMIN-CTR as UMIN000006105.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research